Milestone payments are becoming an increasingly familiar aspect of many biotech deals, as buyers try to mitigate the risks inherent with big purchases. Take Celgene’s $2.9 billion buyout of Abraxis; the biotech giant set aside $650 million in milestone payments if Abraxis’ key drug Abraxane hit certain goals. “These structures are a great way for [...]
Oncologics, lipid regulators, respiratory agents, antidiabetics and anti-ulcerants are the five largest drug classes by sales. But annual sales are only half the story. Which drug classes are booming, and which have plateaued–or even dropped? IMS Health has released top-line industry data revealing the 15 largest drug classes, and we’ve crunched the numbers to take a closer [...]
Eli Lilly (NYSE: LLY) is looking to its pipeline to fill the gaps left by a number of high-profile drugs coming off patent. In October 2011, blockbuster Zyprexa will fall to generic competition; additionally, about three-quarters of Lilly’s current revenue comes from eight drugs that will lose patent protection between now and 2017. ”We have the challenge [...]
In the quest for a cancer vaccine, Merck KGaA is again stepping into the ring. Vaximm Holding AG, the company’s joint venture with a Switzerland’s BB Biotech Ventures III, will start testing a therapeutic cancer vaccine in patients next year. The vaccine, VXM01, harnesses the body’s immune system to fight cancer by using T-cells to close off [...]
Cytori Therapeutics may need to spend $10 million more than anticipated to get clearance for its first product because of a stricter-than-anticipated regulation. Cytori had laid out $200 million in eight years on the device and was seeking ”fast-track” clearance for the body-tissue repair device. But now it must take the slower regulatory path used for about one in every 10 [...]
While many medical professionals continue to debate the effectiveness of mammograms for women prior to age 50, a new study concludes that such tests are becoming more precise in their ability to “detect and intercept” breast cancer, the Group Health Research Institute recently announced. Data from more than 2.5 million screenings for more than 970,000 [...]
The molecular machinery that switches on a gene known to cause breast cancer to spread and invade other organs has been identified by an international team led by scientists at The University of Texas M. D. Anderson Cancer Center. The paper was published in Nature Cell Biology’s advanced online publication.
A federal judge struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property. United States District Court Judge Robert W. Sweet issued the 152-page decision, which invalidated seven patents related to [...]
Monash University biomedical scientists have identified a new way to treat castrate resistant cells in prostate cancer sufferers — the most common cancer in Australian men. For more than 60 years the main way to treat men with prostate cancer has involved removing the hormones that fuel growth of the cancer cells. Although initially effective [...]
Scientists have unveiled new research that suggests that macrophages – the potent immune system cells thought to protect against cancer may actually be promoting metastasis – the deadliest part of the cancer process. Read more about Molecular Targeted Cancer Therapies: Leading Companies Will Hold Onto Competitive Advantage In High Growth Market – A Commercial Insight
You are currently browsing the weblog archives for 'Breast cancer' tag.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Biotech Trading Signals Pharma News Biotech News